Business Context and Reporting Period
This Form 8-K is filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on May 9, 2017. The filing announces the company's financial results for the quarter ended March 31, 2017. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover document referencing the press release but does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached Exhibit 99.1 for these figures.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of the first-quarter results.
Guidance, Outlook, and Risks
The document does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in the press release (Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Important Facts for Investor Verification
- Verify the correct registrant name: The filing is for OvaScience, Inc., despite the metadata request mentioning Tempest Therapeutics, Inc.
- Locate Exhibit 99.1: All specific financial data (revenue, net loss, cash position) is located in the press release titled "OvaScience Reports First Quarter Results," which is not included in the provided text.
- Check the date discrepancy: The Exhibit Index in the text references a press release dated "March 9, 2017," while the filing date and Item 2.02 reference a report date of "May 9, 2017" for the quarter ended March 31, 2017. Investors should verify the correct press release date.
- Legal Status: Note that the financial information is furnished, not filed, limiting its incorporation by reference in other filings.